Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Quality Assurance Regulation topic
No spam. Unsubscribe anytime.
Board committee backs referral of proposed CCR §1711 changes to strengthen pharmacy quality‑assurance reviews
Summary
The Enforcement & Compounding Committee reviewed staff‑draft amendments to CCR §1711 to emphasize aggregate medication‑error analysis, align the definition with BPC 4113.1, and require pharmacies to adopt QA policies and procedures; members requested clearer language and stakeholder guidance before rulemaking.
The California State Board of Pharmacy’s Enforcement and Compounding Committee on April 16 reviewed staff‑proposed amendments to California Code of Regulations section 1711 aimed at strengthening pharmacy quality assurance (QA) programs.
Staff said the draft aligns the regulation’s definition of “medication error” with Business and Professions Code section 4113.1 and moves the regulation toward requiring systematic review of both individual and aggregate medication errors. The proposed language would require pharmacies to establish written policies and procedures defining their QA program, the process for medication‑error review, notification to impacted parties, the frequency of aggregate reports, and the frequency with which the pharmacist in charge (PIC) must review reports. It would also require pharmacies to document how process improvements are communicated to personnel.
Committee members welcomed the emphasis on system‑level learning but raised concerns about vocabulary and implementation. Committee member Renee Barker said the draft’s shift “to be more standard of care” may make compliance harder for small, standalone community pharmacies and suggested FAQs or an implementation guide to ease the transition. Dr. O (committee member) and others cautioned that the term “aggregate” could impose administrative burdens and urged explicit language allowing organizations that own multiple pharmacies to operate joint QA programs if they choose.
Public commenters supported broader QA review and the inclusion of pharmacy technicians in the process. Stephen Gray, a former health system official, urged caution about cross‑jurisdictional data sharing, recommending any shared QA data be limited to within California to preserve statutory confidentiality protections. A pharmacy technician said technician access to verification cues and inclusion in QA review can catch errors earlier and improve patient safety.
Committee members and staff agreed the draft regulation needs clearer, more specific wording in several places (for example, clarifying whether certain items are patient‑specific, prescriber‑specific, or both) and more guidance on the treatment of automated dispensing/packaging machines and reporting thresholds. The committee signaled consensus to refer the draft amendments to the full board for further discussion and to initiate a formal rulemaking process, with staff to return with clarified language and additional stakeholder outreach. No formal committee motion was required to refer the item.
Next steps: the committee recommended the full board consider the draft amendments and noted staff would prepare additional explanatory materials (for example, FAQs) and solicit further stakeholder feedback during rulemaking.
